BMY BRISTOL MYERS SQUIBB CO

CIK 0000014272 50 ready 8-Ks latest May 8, 2026, 7:59 PM ET RSS · JSON

Activity: QUIET 0 filings / 30d vs 1 baseline

Ready 8-Ks 50

Latest filing May 8, 2026, 7:59 PM ET

Top materiality 1.00

Event mix earnings ×17 · other_material ×11 · leadership ×11

Sentiment 10 pos · 2 neg · 38 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for BMY

Highest-materiality recent filing

Bristol Myers Squibb to acquire Karuna Therapeutics for $330/share, ~$14B equity value

December 22, 2023, 6:59 PM ET M&A materiality 1.00 positive item 8.01 item 9.01

Deal valued at $14.0B equity / $12.7B net of cash; 53.4% premium to KRTX Dec 21 close.
Karuna's lead asset KarXT for schizophrenia; PDUFA date Sept 26, 2024; also in trials for Alzheimer's psychosis.

Read filing →

May 8, 2026, 7:59 PM ET other material materiality 0.15 neutral item 5.07 ◈ Shareholder Votes ×5

BMY shareholders elect all 11 directors, pass say-on-pay, stock plan, auditor; independent chair proposal fails

All 11 director nominees elected with >1.46B votes for each.
April 30, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Bristol Myers Q1 revenue $11.5B (+3%); reaffirms 2026 guidance trending upper end

Q1 revenue $11.5B, up 3% YoY (1% ex-FX); Growth Portfolio revenue $6.2B (+12% / +9% ex-FX).
February 5, 2026, 6:59 PM ET earnings materiality 0.75 neutral item 2.02 item 7.01 item 9.01

Bristol Myers Q4 rev $12.5B (+1%), non-GAAP EPS $1.26; dividend raised to $0.63/share; FY2026 guidance rev $46-47.5B

Q4 revenue $12.5B (+1% YoY); Growth Portfolio rev $7.4B (+16%). Full-year rev $48.2B.
January 12, 2026, 6:59 PM ET other material materiality 0.25 neutral item 7.01 item 9.01

Bristol Myers Squibb posts investor presentation at J.P. Morgan Healthcare; no specific updates in filed excerpt

Christopher Boerner, Board Chair & CEO, presented at 44th Annual J.P. Morgan Healthcare Conference on Jan 12, 2026.
November 18, 2025, 6:59 PM ET debt materiality 0.60 neutral item 8.01 item 9.01

BMY completes early settlement of ~$7.5B tender offers for 15 note series

Amended Pool 1 max purchase price to ~$3.99B; Pool 2 max to ~$3.51B.
November 10, 2025, 6:59 PM ET debt materiality 0.50 neutral item 8.01 item 9.01

BMY subsidiary issues €5B notes (2.973%-4.581%) to fund tender offer and general purposes

Issued €5B across five tranches: €750M (2030, 2.973%), €1.15B (2033, 3.363%), €1.15B (2038, 3.857%), €750M (2045, 4.289%), €1.2B (2055, 4.581%).
November 3, 2025, 6:59 PM ET debt materiality 0.75 neutral item 8.01 item 9.01

Bristol-Myers Squibb launches $7B cash tender offer for 15 series of outstanding notes

Offers up to $4B for Pool 1 notes (2026-2029 maturities) and $3B for Pool 2 notes (2031-2097).
October 30, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Bristol Myers Q3 revenue $12.2B (+3% YoY), GAAP EPS $1.08, raises FY revenue guidance to ~$47.5-48B

Total revenues $12,222M (+3% YoY; +2% ex-FX); Growth Portfolio $6.9B (+18% ex-FX).
July 31, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

BMY Q2 revenue $12.3B, GAAP EPS $0.64, non-GAAP EPS $1.46; raises revenue guidance

Revenue $12.3B, +1% YoY; Growth Portfolio $6.6B, +18% YoY (+17% ex-FX).
July 25, 2025, 7:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01

Bristol Myers Squibb appoints Cristian Massacesi as CMO; Samit Hirawat departs by Nov 1

Cristian Massacesi, M.D., named EVP, Chief Medical Officer and Head of Development, effective August 1, 2025.
May 7, 2025, 7:59 PM ET other material materiality 0.15 neutral item 5.07

BMY shareholders elect all 11 directors, approve compensation, at 2025 annual meeting

All 11 director nominees elected; votes 'for' ranged from 1.49B to 1.53B.
April 24, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02 item 7.01 item 9.01

Bristol-Myers Squibb Q1 revenue $11.2B (-6% YoY), GAAP EPS $1.20, raises FY guidance

Total revenues $11.2B, down 6% (4% ex-FX) from $11.865B in Q1 2024.
February 18, 2025, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 ◈ executive_change

Bristol-Myers General Counsel Sandra Leung to retire in 2025

Sandra Leung notified company of her retirement from EVP, General Counsel role, effective in 2025.
February 6, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 7.01 item 9.01

BMY Q4 rev +8% to $12.3B, GAAP EPS $0.04; expands cost-savings by $2B

Q4 2024 revenues $12.3B (+8% YoY, +9% ex-FX); GAAP EPS $0.04, Non-GAAP EPS $1.67.
January 13, 2025, 6:59 PM ET other material materiality 0.20 neutral item 7.01 item 9.01

Bristol-Myers Squibb posts investor presentation at J.P. Morgan Healthcare Conference

Presentation posted on Jan 13, 2025, by CEO Christopher Boerner at the 43rd Annual J.P. Morgan Healthcare Conference.
October 31, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Bristol Myers Q3 2024 revenue $11.9B (+8% YoY); raises full-year guidance, Cobenfy approved

Q3 2024 revenues $11.9B, up 8% (+10% ex-FX); GAAP EPS $0.60, Non-GAAP EPS $1.80.
July 26, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01

Bristol Myers Q2 rev $12.2B (+9%), non-GAAP EPS $2.07, raises FY guidance

Revenues $12.2B up 9% YoY (+11% ex-FX); Growth Portfolio $5.6B up 18% (+21% ex-FX).
June 18, 2024, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 item 9.01 ◈ executive_change

Bristol Myers Squibb elects former Agilent CEO Michael McMullen to board

Michael R. McMullen elected to board, effective July 1, 2024; board size increases to 11.
May 9, 2024, 7:59 PM ET other materiality 0.20 neutral item 5.03 item 5.07 item 9.01 ◈ Shareholder Votes ×6

Bristol-Myers Squibb shareholders approve charter amendment limiting executive officer liability, elect directors

Amendment to eliminate/limit monetary liability for breach of duty of care for specified executive officers approved by majority of outstanding shares.
April 25, 2024, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Bristol-Myers Squibb Q1 revenue up 5% to $11.9B; GAAP loss per share $5.89 on acquired IPRD charges

Q1 revenues $11,865M (+5% reported, +6% ex-FX); growth portfolio revenues $4,767M (+8%, +11% ex-FX).
March 18, 2024, 7:59 PM ET M&A materiality 0.85 neutral item 8.01 item 9.01

Bristol-Myers Squibb completes $330/share acquisition of Karuna Therapeutics, adds schizophrenia drug KarXT

Each Karuna share converted into $330 cash; deal closed March 18, 2024.
March 18, 2024, 7:59 PM ET leadership materiality 0.25 neutral item 5.02 ◈ executive_change

Bristol-Myers director Gerald Storch not seeking re-election; board size set to ten

Gerald Storch notified the Board on March 13, 2024, that he will not stand for re-election at the 2024 Annual Meeting.
February 22, 2024, 6:59 PM ET debt materiality 0.80 neutral item 8.01 item 1.01 item 9.01

BMY closes $13.5B multi-tranche note offering to fund Karuna and RayzeBio acquisitions

Issued nine tranches totaling $13.5B: Floating Rate Notes (2026) and fixed-rate notes from 2026 to 2064.
February 15, 2024, 6:59 PM ET leadership materiality 0.35 neutral item 5.02 item 9.01 ◈ executive_change ×2

Bristol-Myers Squibb appoints Phil Holzer as Senior VP & Controller effective Feb 15, 2024

Phil Holzer appointed Senior Vice President and Controller, succeeding Sharon Greenlees who will move to another role.
February 14, 2024, 6:59 PM ET other material materiality 0.30 neutral item 8.01 item 9.01

BMY warns shareholders about unsolicited mini-tender offer at $55/share

Tutanota LLC offered $55/share for up to 500k BMY shares (<0.025% of outstanding).
February 2, 2024, 6:59 PM ET earnings materiality 0.80 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×2

Bristol Myers Q4 rev up 1% to $11.5B; Non-GAAP EPS $1.70; FY rev $45.0B; 2024 EPS guide $7.10-$7.40

Fourth quarter revenues $11.5B (+1% YoY); GAAP EPS $0.87, Non-GAAP EPS $1.70.
January 8, 2024, 6:59 PM ET other material materiality 0.15 neutral item 7.01 item 9.01

Bristol-Myers Squibb posts investor presentation for J.P. Morgan; details not in filing text

Presentation dated January 8, 2024, posted on BMS investor website.
December 22, 2023, 6:59 PM ET M&A materiality 1.00 positive item 8.01 item 9.01

Bristol Myers Squibb to acquire Karuna Therapeutics for $330/share, ~$14B equity value

Deal valued at $14.0B equity / $12.7B net of cash; 53.4% premium to KRTX Dec 21 close.
November 13, 2023, 6:59 PM ET debt materiality 0.65 neutral item 8.01 item 9.01

Bristol-Myers Squibb completes $4.5B note offering to finance Mirati acquisition

$4.5B note offering completed: $1B 5.75% due 2031, $1B 5.9% due 2033, $1.25B 6.25% due 2053, $1.25B 6.4% due 2063.
October 31, 2023, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change ×4

Bristol-Myers details CEO succession; Caforio to retire April 1, 2024, Boerner Chairman

Giovanni Caforio steps down as CEO, becomes Executive Chairman Nov 1, 2023, then retires from Board April 1, 2024.
October 26, 2023, 7:59 PM ET earnings materiality 0.80 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Bristol-Myers Q3 rev $10.97B; GAAP EPS $0.93, non-GAAP $2.00; Mirati acquisition

Q3 revenues $10,966M, down 2% YoY (3% ex-FX); GAAP EPS $0.93 (+24%), non-GAAP EPS $2.00 (+1%).
August 10, 2023, 7:59 PM ET other material materiality 0.70 positive item 8.01

Bristol-Myers Squibb enters $4B accelerated share repurchase with four banks

Entered ASR agreements with Bank of America, Citibank, JPMorgan Chase, and Morgan Stanley to repurchase $4.0B of common stock.
July 27, 2023, 7:59 PM ET earnings materiality 0.85 negative item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

BMY Q2 revenue $11.2B, GAAP EPS $0.99, non-GAAP $1.75; cuts FY guidance on Revlimid decline

Q2 revenue $11.2B, down 6% YoY (5% ex-FX); GAAP EPS $0.99 (up 50% YoY), non-GAAP EPS $1.75 (down 9% YoY).
May 4, 2023, 7:59 PM ET leadership materiality 0.70 neutral item 5.02 item 5.07 ◈ Shareholder Votes ×7◈ executive_change ×3

Bristol-Myers appoints COO and CEO-elect; shareholders elect board

Christopher Boerner named COO effective Apr 26, 2023 and CEO effective Nov 1, 2023; elected to Board May 2, 2023.
April 27, 2023, 7:59 PM ET earnings materiality 0.80 positive item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Bristol Myers Q1 revenue $11.3B, GAAP EPS $1.07, Non-GAAP $2.05; affirms non-GAAP guidance

Q1 2023 revenues $11.3B, down 3% YoY; in-line & new product portfolio grew 8% (10% ex-FX).
April 26, 2023, 7:59 PM ET leadership materiality 0.75 neutral item 5.02 item 9.01 ◈ executive_change ×3

Bristol-Myers Squibb CEO Giovanni Caforio to retire Nov 1; Christopher Boerner named CEO successor

Giovanni Caforio to retire as CEO effective Nov 1, 2023; will become Executive Chairman for transition period.
February 28, 2023, 6:59 PM ET other material materiality 0.15 neutral item 8.01

Bristol-Myers reports no CVR payment due for Abraxane 2022 net sales of $909M

2022 Abraxane net sales of $908,974,933 triggered no payment under Celgene CVR agreement.
February 2, 2023, 6:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases ×3

Bristol Myers Q4 revenue $11.4B, GAAP EPS $0.95; full-year $46.2B, EPS $2.95; in-line/new product portfolio grows 7%

Q4 2022 revenues $11,406M (-5% YoY); full-year $46,159M (flat YoY).
January 31, 2023, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01 ◈ executive_change

Bristol-Myers EVP Research & Early Development Rupert Vessey to depart July 2023

Dr. Rupert Vessey, EVP Research and Early Development, leaves effective July 3, 2023.
January 9, 2023, 6:59 PM ET other material materiality 0.10 neutral item 7.01 item 9.01

BMY posts investor presentation for JP Morgan Conference on Jan 9, 2023

Company made an investor presentation available on its website; specific content not provided in filing.
October 26, 2022, 7:59 PM ET earnings materiality 0.70 neutral item 2.02 item 7.01 item 9.01

BMY Q3 revenue $11.2B (-3% YoY), GAAP EPS $0.75, Non-GAAP $1.99

Revenue $11.2B, down 3% vs Q3 2021; U.S. revenue up 9% to $7.9B, international down 24% to $3.3B.
July 27, 2022, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 7.01 item 9.01

Bristol-Myers Q2 revenue $11.9B (+2% YoY); Non-GAAP EPS $1.93 (+18%); GAAP EPS guidance adjusted

Q2 revenue $11.887B, up 2% (5% ex-FX); U.S. revenue +12% to $8.3B, international revenue -16% (-8% ex-FX).
June 15, 2022, 7:59 PM ET leadership materiality 0.30 neutral item 5.02 item 9.01 ◈ executive_change

Bristol-Myers Squibb elects Dr. Deepak L. Bhatt to Board of Directors

Dr. Deepak L. Bhatt elected to Board effective June 14, 2022; Board size increases to 11.
May 5, 2022, 7:59 PM ET other material materiality 0.15 neutral item 5.07

Bristol-Myers annual meeting: all directors elected, shareholder proposals rejected

All 10 director nominees elected; votes ranged from 1.44B (Caforio) to 1.54B (Haller).
April 29, 2022, 7:59 PM ET earnings materiality 0.85 neutral item 2.02 item 7.01 item 9.01

Bristol-Myers Q1 revenue $11.6B (+5%); Non-GAAP EPS $1.96 (+13%)

Revenue $11.648B, +5% YoY (7% ex FX); U.S. revenue $7.7B (+10%).
April 18, 2022, 7:59 PM ET other material materiality 0.60 negative item 2.02 item 9.01

Bristol-Myers to revise non-GAAP reporting; Q1 2022 impact of -$0.10/share from Acquired IPRD

Starting Q1 2022, non-GAAP results will include significant R&D charges from asset acquisitions and licensing, previously excluded.
March 17, 2022, 7:59 PM ET leadership materiality 0.40 neutral item 5.02 ◈ executive_change ×2

Bristol-Myers appoints Sharon Greenlees as new SVP and Controller

Sharon Greenlees becomes Senior VP and Controller effective April 25, 2022; most recently at AbbVie as VP and Controller, R&D Finance.
March 3, 2022, 6:59 PM ET debt materiality 0.50 neutral item 8.01 item 9.01

Bristol-Myers Squibb upsizes note tender offers, accepts ~$5.15B principal, early settlement March 4

Upsized maximum aggregate purchase price from $4.0B to accept all valid tenders; accepted ~$5.15B principal across 22 series.
March 2, 2022, 6:59 PM ET debt materiality 0.60 neutral item 1.01 item 2.03 item 9.01

Bristol-Myers Squibb issues $6B in notes across 2032-2062 maturities

Completed $6B offering: $1.75B 2.95% notes due 2032, $1.25B 3.55% due 2042, $2B 3.70% due 2052, $1B 3.90% due 2062.
February 24, 2022, 6:59 PM ET other materiality 0.25 neutral item 8.01

BMY reports 2021 Abraxane net sales of $1.18B, triggers $4.5M CVR payment

Abraxane net sales for 2021: $1,181,043,283 as recorded in BMY financial statements.

Executive changes

Departed

Sandra Leung

Executive Vice President, General Counsel

BMY · BRISTOL MYERS SQUIBB CO

Filed: February 18, 2025, 6:59 PM ET

On February 14 , 2025, Sandra Leung notified Bristol-Myers Squibb Company (the “Company”) of her intention to retire from her position as Executive Vice President, General Counsel in 2025.

Appointed

Michael R. McMullen

Director

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2024-07-01
Filed: June 18, 2024, 7:59 PM ET

On June 18, 2024, the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) elected Mr. Michael R. McMullen to serve as a member of the Board, effective July 1, 2024.

Departed

Gerald Storch

Director

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2024-05-07
Filed: March 18, 2024, 7:59 PM ET

On March 13, 2024, Mr. Gerald Storch notified the Board of Directors (the "Board") of Bristol-Myers Squibb Company (the "Company") that he will not stand for re-election to the Board of the Company at the 2024 Annual Meeting of Shareholders.

Role change

Sharon Greenlees

Senior Vice President and Controller

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2024-02-15
Successor: Phil Holzer
Filed: February 15, 2024, 6:59 PM ET

Ms. Sharon Greenlees, Senior Vice President and Controller, will assume another role at the Company, effective February 15, 2024.

Appointed

Phil Holzer

Senior Vice President and Controller

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2024-02-15
Filed: February 15, 2024, 6:59 PM ET

Effective February 15, 2024, Mr. Phil Holzer will be appointed Senior Vice President and Controller of Bristol-Myers Squibb Company

Departed

Giovanni Caforio

Director

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2024-04-01
Filed: October 31, 2023, 7:59 PM ET

On October 25, 2023, Dr. Caforio advised the Board that he will not stand for re-election to the Board at the 2024 Annual Meeting of Shareholders, and will retire from the Board, effective April 1, 2024.

Appointed

Christopher Boerner

Chief Executive Officer

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2023-11-01
Filed: October 31, 2023, 7:59 PM ET

appointment of Christopher Boerner, Ph.D. as Chief Executive Officer by the Board, effective November 1, 2023

Appointed

Christopher Boerner

Chairman of the Board

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2024-04-01
Filed: October 31, 2023, 7:59 PM ET

the Board approved the appointment of Dr. Boerner as Chairman of the Board in addition to Chief Executive Officer, effective April 1, 2024

Role change

Giovanni Caforio

Executive Chairman

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2023-11-01
Successor: Christopher Boerner
Filed: October 31, 2023, 7:59 PM ET

retirement of Giovanni Caforio, M.D. as Chief Executive Officer and his election as Executive Chairman of the Board of Directors of the Company (the “Board”), effective November 1, 2023

Appointed

Christopher Boerner

Director

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2023-05-02
Filed: May 4, 2023, 7:59 PM ET

the Board elected Dr. Boerner, to serve as a member of the Board, effective May 2, 2023

Appointed

Christopher Boerner

Chief Operating Officer

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2023-04-26
Filed: May 4, 2023, 7:59 PM ET

appointed Christopher Boerner, Ph.D., to serve as the Company’s Chief Operating Officer, effective April 26, 2023

Appointed

Christopher Boerner

Chief Executive Officer

BMY · BRISTOL MYERS SQUIBB CO

Effective: 2023-11-01
Filed: May 4, 2023, 7:59 PM ET

and as the Chief Executive Officer, effective November 1, 2023

Earnings & guidance

2026-Q1 EPS reported $1.31 filing →

Materiality & sentiment trend

Max materiality 1.00 · Median 0.62 · Most common event earnings

10 positive 2 negative 38 neutral

source · BMY on sec.gov